Cargando…
Drug repurposing against COVID-19: focus on anticancer agents
BACKGROUND: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a globa...
Autores principales: | Ciliberto, Gennaro, Mancini, Rita, Paggi, Marco G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214852/ https://www.ncbi.nlm.nih.gov/pubmed/32398164 http://dx.doi.org/10.1186/s13046-020-01590-2 |
Ejemplares similares
-
Boosting the arsenal against COVID-19 through computational drug repurposing
por: Ciliberto, Gennaro, et al.
Publicado: (2020) -
Repurposing anticancer drugs for the management of COVID-19
por: El Bairi, Khalid, et al.
Publicado: (2020) -
Penfluridol as a Candidate of Drug Repurposing for Anticancer Agent
por: Tuan, Nguyen Minh, et al.
Publicado: (2019) -
Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent
por: Yu, Lu, et al.
Publicado: (2023) -
Drug repurposing for the treatment of glioblastoma multiforme
por: Abbruzzese, Claudia, et al.
Publicado: (2017)